Jubilant Pharma gives investors dose of India high yield
Indian generic drugs producer Jubilant Pharma raised $200m from its return to the bond market after investors rushed to snap up a rare Indian high yield credit.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: